AbbVie Sets Full-Year Adjusted EPS Guidance at $14.08-$14.28
ABBV is trading near its 52-week low of $176.57 (12% above the low).
Summary
AbbVie has issued its full-year adjusted EPS guidance, projecting a range of $14.08 to $14.28. This new financial outlook from the company is a critical data point for investors and analysts, who will use it to update their valuation models and expectations for the pharmaceutical giant. While the headline does not provide context on how this guidance compares to previous forecasts or analyst consensus, it represents a direct statement from management on expected profitability. Traders will be closely watching market reaction to this guidance, especially in light of recent product development news, including positive Rinvoq data and an FDA application, alongside a recent FDA rejection for a wrinkle treatment.
At the time of this announcement, ABBV was trading at $197.96 on NYSE in the Life Sciences sector, with a market capitalization of approximately $349.7B. The 52-week trading range was $176.57 to $244.81. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.